Prostate Cancer – Epidemiology Forecast to 2028

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.2 million men were diagnosed with prostate cancer in 2018 (International Agency for Research on Cancer, 2019). Almost all prostate cancers are adenocarcinomas, a type of cancer that develops in gland cells. Most prostate cancers are asymptomatic and grow very slowly. In advanced stages of prostate cancer, the malignancy has spread to other organs such as seminal vesicles, lymph nodes, or bones. When a tumor fails to respond to androgen deprivation therapy, it is referred to as castration-resistant prostate cancer (CRPC) (National Cancer Institute, 2019a). Changes in PSA testing and screening guidelines since 2007 have led to substantial changes in prostate cancer incidence. GlobalData epidemiologists used the most recent data for incidence calculations in the 8MM.
In 2018, the US accounted for 30.46% of the diagnosed incident cases of prostate cancer in the 8MM, with 170,744 cases. There were 216,980 cases in the 5EU in 2018, or 38.71% of the diagnosed incident cases, while Japan had 93,916 diagnosed incident cases and China had 78,874 diagnosed incident cases. In the 8MM, the number of diagnosed incident cases of prostate cancer will grow by 19.41% over the forecast period at an Annual Growth Rate (AGR) of 1.94% from 560,514 cases in 2018 to 669,284 cases by 2028. Of the 8MM, the US is expected to have the highest number of diagnosed incident cases, increasing from 170,744 cases in 2018 to 204,127 cases in 2028. Italy had the lowest number of diagnosed incident cases of prostate cancer in 2018, at 35,300 cases. Any change in the diagnosed incident cases of prostate cancer in the 8MM is attributable to changing population demographics in the respective markets.

Scope

The Prostate Cancer Epidemiology Report and Model provide an overview of the risk factors and global trends of prostate cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).

This report includes 10-year epidemiological forecast for diagnosed incident cases of prostate cancer in men segmented by age (beginning at 30 years), Gleason scores (2–10), stage at diagnosis (stage I, II, III, IV-M0, and IV-M1), risk category (very low/low risk, intermediate risk, and high/very high risk), and metastatic cases at diagnosis (bone metastases only and bone metastases with visceral metastases) in these markets. Additionally, this report forecasts five-year diagnosed prevalent cases of prostate cancer segmented by castration resistance and metastases.

The prostate cancer epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The Prostate Cancer Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.

Quantify patient populations in the global prostate cancer market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups that present the best opportunities for prostate cancer therapeutics in each of the markets covered.

Understand magnitude of prostate cancer by stage at diagnosis and risk category.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Prostate Cancer: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods, Population

3.4.3 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer

3.4.4 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer by Gleason Scores

3.4.5 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis

3.4.6 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer by Risk Category

3.4.7 Forecast Assumptions and Methods, Metastatic Cases at Diagnosis

3.4.8 Forecast Assumptions and Methods, Five-Year Diagnosed Prevalent Cases of Prostate Cancer

3.4.9 Forecast Assumptions and Methods, Five-Year Diagnosed Prevalent Cases (Metastatic and Non-Metastatic) that Progress from Hormone-Sensitive Disease to CRPC by Status

3.5 Epidemiological Forecast for Prostate Cancer (2018–2028)

3.5.1 Diagnosed Incident Cases of Prostate Cancer

3.5.2 Age-Specific Incident Cases of Prostate Cancer

3.5.3 Diagnosed Incident Cases of Prostate Cancer by Gleason Score

3.5.4 Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis

3.5.5 Diagnosed Incident Cases of Prostate Cancer by Risk Category

3.5.6 Metastatic Cases at Diagnosis

3.5.7 Five-Year Diagnosed Prevalent Cases of Prostate Cancer

3.5.8 Diagnosed Five-Year Prevalent Cases of Prostate Cancer that Progress from Hormone-Sensitive Disease to CRPC by Status

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitations of Analysis

3.6.3 Strengths of Analysis

4 Appendix

4.1 Bibliography

4.2 Primary Market Research – Prescriber Survey

4.3 Abbreviations

4.4 About the Authors

4.4.1 Epidemiologist

4.4.2 Reviewers

4.4.3 Global Director of Therapy Analysis and Epidemiology

4.4.4 Global Head and EVP of Healthcare Operations and Strategy

4.5 About GlobalData

4.6 Contact Us

4.7 Disclaimer

Table

Table 1: Risk Factors and Comorbidities for Prostate Cancer

Table 2: AJCC Staging of Prostate Cancer

Table 3: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country and Specialty

Figures

Figure 1: 8MM, Diagnosed Incident Cases of Prostate Cancer, Ages ≥30 Years, Men, N, 2018 and 2028

Figure 2: 8MM, Five-Year Diagnosed Prevalent Cases of Prostate Cancer, Ages ≥30 Years, Men, N, 2018 and 2028

Figure 3: 8MM, Diagnosed Incidence of Prostate Cancer, Men, Ages ≥30 Years, 2008–2028

Figure 4: 8MM, Sources Used, Diagnosed Incident Cases of Prostate Cancer

Figure 5: 8MM, Sources Used, Diagnosed Incident Cases of Prostate Cancer by Gleason Scores

Figure 6: 8MM, Sources Used, Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis

Figure 7: 8MM, Sources Used, Diagnosed Incident Cases of Prostate Cancer by Risk Category

Figure 8: 8MM, Sources Used, Metastatic Cases at Diagnosis

Figure 9: 8MM, Sources Used, Five-Year Diagnosed Prevalent Cases of Prostate Cancer

Figure 10: 8MM, Sources Used, Five-Year Diagnosed Prevalent Cases of Prostate Cancer by Progression from Hormone-Sensitive Disease to CRPC

Figure 11: 8MM, Sources Used, Five-Year Diagnosed Prevalent Cases of Prostate Cancer by Progression from Hormone-Sensitive Disease to CRPC by Status

Figure 12: 8MM, Diagnosed Incident Cases of Prostate Cancer, Ages ≥30 Years, Men, N, 2018

Figure 13: 8MM, Age-Specific Diagnosed Incident Cases of Prostate Cancer, Men, N, 2018

Figure 14: 8MM, Diagnosed Incident Cases of Prostate Cancer by Gleason Score, Ages ≥30 Years, Men, N, 2018

Figure 15: 8MM, Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis, Ages ≥30 Years, Men, N, 2018

Figure 16: 8MM, Diagnosed Incident Cases of Prostate Cancer by Risk Category, Ages ≥30 Years, Men, N, 2018

Figure 17: 8MM, Metastatic Cases at Diagnosis, Ages ≥30 Years, Men, N, 2018

Figure 18: 8MM, Five-Year Diagnosed Prevalent Cases of Prostate Cancer, Ages ≥30 Years, Men, N, 2018

Figure 19: 8MM, Diagnosed Five-Year Prevalent Cases of Prostate Cancer that Progress from Hormone-Sensitive Disease to CRPC by Status, Ages ≥30 Years, Men, N, 2018

Frequently asked questions

Prostate Cancer – Epidemiology Forecast to 2028 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Prostate Cancer – Epidemiology Forecast to 2028 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Prostate Cancer – Epidemiology Forecast to 2028 in real time.

  • Access a live Prostate Cancer – Epidemiology Forecast to 2028 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.